Concepts (184)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genome, Viral | 1 | 2021 | 12 | 0.800 |
Why?
|
| Transcription, Genetic | 2 | 2013 | 136 | 0.510 |
Why?
|
| Neoplasms | 3 | 2020 | 608 | 0.490 |
Why?
|
| Drug Discovery | 1 | 2013 | 30 | 0.470 |
Why?
|
| Brain Neoplasms | 5 | 2022 | 581 | 0.420 |
Why?
|
| Antineoplastic Agents | 2 | 2011 | 546 | 0.360 |
Why?
|
| Appendiceal Neoplasms | 2 | 2020 | 81 | 0.340 |
Why?
|
| Peritoneal Neoplasms | 2 | 2020 | 241 | 0.300 |
Why?
|
| Glioblastoma | 2 | 2022 | 143 | 0.290 |
Why?
|
| Computational Biology | 5 | 2020 | 86 | 0.290 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 401 | 0.280 |
Why?
|
| Models, Biological | 4 | 2017 | 372 | 0.280 |
Why?
|
| Humans | 23 | 2022 | 28998 | 0.270 |
Why?
|
| Systems Biology | 2 | 2016 | 9 | 0.220 |
Why?
|
| Mice | 9 | 2020 | 2368 | 0.220 |
Why?
|
| Animals | 11 | 2020 | 7296 | 0.210 |
Why?
|
| Gene Regulatory Networks | 2 | 2020 | 35 | 0.200 |
Why?
|
| Cell Line, Tumor | 6 | 2022 | 680 | 0.200 |
Why?
|
| Cardiovascular Diseases | 1 | 2008 | 1007 | 0.190 |
Why?
|
| Glioma | 1 | 2022 | 132 | 0.190 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2020 | 20 | 0.180 |
Why?
|
| Software | 3 | 2019 | 109 | 0.180 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2019 | 2 | 0.180 |
Why?
|
| Lymphopoiesis | 1 | 2019 | 4 | 0.180 |
Why?
|
| Bone Neoplasms | 2 | 2018 | 104 | 0.180 |
Why?
|
| Magnetic Field Therapy | 1 | 2019 | 17 | 0.180 |
Why?
|
| Interleukin-4 | 1 | 2019 | 20 | 0.170 |
Why?
|
| Interleukin-1beta | 1 | 2019 | 41 | 0.170 |
Why?
|
| Calcium Channels, T-Type | 1 | 2019 | 29 | 0.170 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 91 | 0.170 |
Why?
|
| Myeloid Cells | 1 | 2019 | 35 | 0.170 |
Why?
|
| Signal Transduction | 4 | 2019 | 666 | 0.170 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2019 | 60 | 0.170 |
Why?
|
| Transforming Growth Factor beta | 1 | 2019 | 66 | 0.170 |
Why?
|
| Breast Neoplasms | 3 | 2018 | 666 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2018 | 19 | 0.160 |
Why?
|
| Microfilament Proteins | 1 | 2018 | 33 | 0.160 |
Why?
|
| Microglia | 1 | 2018 | 48 | 0.160 |
Why?
|
| Neoplastic Stem Cells | 2 | 2019 | 90 | 0.160 |
Why?
|
| STAT3 Transcription Factor | 1 | 2018 | 22 | 0.160 |
Why?
|
| Exosomes | 1 | 2018 | 38 | 0.160 |
Why?
|
| Protein Interaction Mapping | 1 | 2017 | 8 | 0.160 |
Why?
|
| Receptor, erbB-2 | 1 | 2018 | 45 | 0.160 |
Why?
|
| Incidence | 1 | 2021 | 1105 | 0.160 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 162 | 0.150 |
Why?
|
| Calcium | 1 | 2019 | 296 | 0.150 |
Why?
|
| Hematologic Diseases | 1 | 2017 | 23 | 0.150 |
Why?
|
| Models, Statistical | 1 | 2017 | 160 | 0.140 |
Why?
|
| Pharmaceutical Preparations | 2 | 2013 | 29 | 0.140 |
Why?
|
| MicroRNAs | 1 | 2018 | 173 | 0.140 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2018 | 173 | 0.140 |
Why?
|
| Cell Line | 4 | 2020 | 449 | 0.140 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 131 | 0.140 |
Why?
|
| Models, Genetic | 1 | 2015 | 92 | 0.130 |
Why?
|
| Chloroquine | 1 | 2014 | 2 | 0.130 |
Why?
|
| Janus Kinase 2 | 1 | 2014 | 4 | 0.130 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 97 | 0.120 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 301 | 0.120 |
Why?
|
| Female | 11 | 2020 | 18112 | 0.120 |
Why?
|
| Transcription Factors | 1 | 2015 | 172 | 0.120 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2013 | 58 | 0.120 |
Why?
|
| Pharmacology | 1 | 2013 | 3 | 0.120 |
Why?
|
| Drug Industry | 1 | 2013 | 14 | 0.120 |
Why?
|
| Drug Delivery Systems | 1 | 2013 | 92 | 0.110 |
Why?
|
| Brain | 2 | 2018 | 928 | 0.110 |
Why?
|
| Gene Expression Profiling | 3 | 2020 | 320 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2011 | 11 | 0.100 |
Why?
|
| Prognosis | 3 | 2020 | 1362 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 77 | 0.100 |
Why?
|
| Alzheimer Disease | 1 | 2013 | 312 | 0.090 |
Why?
|
| Mice, Nude | 3 | 2018 | 276 | 0.090 |
Why?
|
| Mass Spectrometry | 1 | 2008 | 99 | 0.080 |
Why?
|
| Cell Proliferation | 3 | 2018 | 573 | 0.080 |
Why?
|
| Survival Rate | 2 | 2020 | 795 | 0.080 |
Why?
|
| Sulfides | 2 | 2018 | 24 | 0.080 |
Why?
|
| Caprylates | 2 | 2018 | 25 | 0.080 |
Why?
|
| Up-Regulation | 2 | 2018 | 183 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2018 | 249 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 2 | 2020 | 160 | 0.070 |
Why?
|
| Aged | 4 | 2020 | 9461 | 0.070 |
Why?
|
| Middle Aged | 4 | 2020 | 10805 | 0.060 |
Why?
|
| Phenotype | 2 | 2019 | 629 | 0.060 |
Why?
|
| Neoplasm Metastasis | 2 | 2016 | 199 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 980 | 0.060 |
Why?
|
| Adult | 3 | 2020 | 8391 | 0.050 |
Why?
|
| MAP Kinase Signaling System | 2 | 2013 | 57 | 0.050 |
Why?
|
| Ubiquitination | 1 | 2022 | 14 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 2 | 2013 | 81 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2022 | 36 | 0.050 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2022 | 72 | 0.050 |
Why?
|
| Male | 4 | 2020 | 17767 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2019 | 3094 | 0.050 |
Why?
|
| Co-Repressor Proteins | 1 | 2020 | 3 | 0.050 |
Why?
|
| Immune System Phenomena | 1 | 2020 | 2 | 0.050 |
Why?
|
| Oncogenes | 1 | 2020 | 6 | 0.050 |
Why?
|
| Bone Morphogenetic Protein 7 | 1 | 2020 | 18 | 0.050 |
Why?
|
| Immunologic Factors | 1 | 2020 | 48 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2020 | 67 | 0.040 |
Why?
|
| Interleukin-9 | 1 | 2019 | 2 | 0.040 |
Why?
|
| Calcium Channel Blockers | 1 | 2019 | 49 | 0.040 |
Why?
|
| Radiometry | 1 | 2019 | 39 | 0.040 |
Why?
|
| Interleukin-1 | 1 | 2019 | 33 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2019 | 77 | 0.040 |
Why?
|
| Melanoma, Experimental | 1 | 2019 | 10 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 73 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2019 | 22 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2019 | 35 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 113 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2019 | 75 | 0.040 |
Why?
|
| RNA, Small Interfering | 1 | 2019 | 109 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 523 | 0.040 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2020 | 146 | 0.040 |
Why?
|
| Genomics | 1 | 2019 | 82 | 0.040 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2018 | 6 | 0.040 |
Why?
|
| Cell Respiration | 1 | 2018 | 21 | 0.040 |
Why?
|
| Mitoxantrone | 1 | 2018 | 17 | 0.040 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2018 | 33 | 0.040 |
Why?
|
| Retreatment | 1 | 2018 | 40 | 0.040 |
Why?
|
| Spheroids, Cellular | 1 | 2018 | 28 | 0.040 |
Why?
|
| Cytarabine | 1 | 2018 | 52 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2018 | 76 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2018 | 142 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 706 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2018 | 48 | 0.040 |
Why?
|
| Bone Marrow | 1 | 2018 | 60 | 0.040 |
Why?
|
| RNA-Binding Proteins | 1 | 2018 | 68 | 0.040 |
Why?
|
| Hypoalbuminemia | 1 | 2017 | 9 | 0.040 |
Why?
|
| Lymphopenia | 1 | 2017 | 11 | 0.040 |
Why?
|
| Leucovorin | 1 | 2017 | 20 | 0.040 |
Why?
|
| Hypokalemia | 1 | 2017 | 14 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2017 | 66 | 0.040 |
Why?
|
| Neutropenia | 1 | 2017 | 23 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2018 | 225 | 0.040 |
Why?
|
| Sensation Disorders | 1 | 2017 | 19 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 89 | 0.040 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 32 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2017 | 56 | 0.040 |
Why?
|
| Recurrence | 1 | 2018 | 235 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 2018 | 138 | 0.040 |
Why?
|
| Organoplatinum Compounds | 1 | 2017 | 42 | 0.040 |
Why?
|
| Camptothecin | 1 | 2017 | 48 | 0.040 |
Why?
|
| Abdominal Pain | 1 | 2017 | 40 | 0.040 |
Why?
|
| Anemia | 1 | 2017 | 55 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2017 | 73 | 0.040 |
Why?
|
| Biopsy | 1 | 2018 | 241 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2018 | 440 | 0.040 |
Why?
|
| Hyperglycemia | 1 | 2017 | 82 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2019 | 436 | 0.040 |
Why?
|
| Mutation | 1 | 2019 | 466 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 436 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2018 | 256 | 0.040 |
Why?
|
| Mitochondria | 1 | 2018 | 174 | 0.040 |
Why?
|
| Sepsis | 1 | 2017 | 146 | 0.030 |
Why?
|
| Transcription Initiation Site | 1 | 2015 | 10 | 0.030 |
Why?
|
| Histones | 1 | 2015 | 49 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2016 | 126 | 0.030 |
Why?
|
| Protein Binding | 1 | 2015 | 199 | 0.030 |
Why?
|
| Genome, Human | 1 | 2015 | 129 | 0.030 |
Why?
|
| Autophagy | 1 | 2014 | 53 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2013 | 19 | 0.030 |
Why?
|
| Astrocytes | 1 | 2013 | 49 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 69 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 57 | 0.030 |
Why?
|
| Technology, Pharmaceutical | 1 | 2013 | 3 | 0.030 |
Why?
|
| Computer Graphics | 1 | 2013 | 11 | 0.030 |
Why?
|
| Automation | 1 | 2013 | 30 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2013 | 81 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2013 | 44 | 0.030 |
Why?
|
| Drug Design | 1 | 2013 | 44 | 0.030 |
Why?
|
| RNA Interference | 1 | 2013 | 76 | 0.030 |
Why?
|
| Artificial Intelligence | 1 | 2013 | 49 | 0.030 |
Why?
|
| Cell Movement | 1 | 2013 | 161 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2020 | 3100 | 0.030 |
Why?
|
| Internet | 1 | 2013 | 156 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2013 | 855 | 0.030 |
Why?
|
| Aminoacetonitrile | 1 | 2011 | 1 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2013 | 241 | 0.030 |
Why?
|
| Young Adult | 1 | 2018 | 2398 | 0.020 |
Why?
|
| Sirolimus | 1 | 2011 | 35 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 481 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2011 | 189 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2013 | 383 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 641 | 0.020 |
Why?
|
| United States | 1 | 2013 | 3604 | 0.020 |
Why?
|